Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

401. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. (PubMed)

Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Randomized trials of short-term aspirin use for prevention of recurrent colorectal adenoma have provided compelling evidence of a causal relationship between aspirin and colorectal neoplasia. However, data on long-term risk of colorectal cancer according to dose, timing, or duration of therapy with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) remain limited.To examine (...) the influence of aspirin and NSAIDs in prevention of colorectal cancer.Prospective cohort study of 82 911 women enrolled in the Nurses' Health Study providing data on medication use biennially since 1980 and followed up through June 1, 2000.Incident colorectal cancer.Over a 20-year period, we documented 962 cases of colorectal cancer. Among women who regularly used aspirin (> or =2 standard [325-mg] tablets per week), the multivariate relative risk (RR) for colorectal cancer was 0.77 (95% confidence

Full Text available with Trip Pro

2005 JAMA

402. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. (PubMed)

Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. To investigate the routine use of low dose aspirin in people aged > or = 70 without overt cardiovascular disease.Epidemiological modelling in a hypothetical population.Reference populations of men and women in the year 2000 from the state of Victoria, Australia.10,000 men and 10,000 women aged 70-74 with no cardiovascular disease.First ever (...) myocardial infarction or unstable angina, ischaemic or haemorrhagic stroke, and major gastrointestinal haemorrhage. Health adjusted years of life lived.The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (-389 in men, -321 in women) and ischaemic stroke (-19 in men and -35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding. The results in health adjusted years of life lived

Full Text available with Trip Pro

2005 BMJ

403. Aspirin in the treatment of acute pulmonary embolism

Aspirin in the treatment of acute pulmonary embolism BestBets: Aspirin in the treatment of acute pulmonary embolism Aspirin in the treatment of acute pulmonary embolism Report By: Caroline Lee - Senior Clinical Fellow Search checked by Craig Ferguson - Clinical Research Fellow Institution: Manchester Royal Infirmary Date Submitted: 2nd November 2004 Date Completed: 18th May 2005 Last Modified: 18th May 2005 Status: Green (complete) Three Part Question In [a patient with suspected acute (...) pulmonary embolus] is [aspirin] effective in [reducing morbidity and mortality]? Clinical Scenario A 50 year old woman presents to the emergency department with shortness of breath and pleurtic chest pain, following a flight from Australia. Examination is unremarkable except for tachypnoea and mild hypoxia. CXR is also normal, so you aim to treat for suspected pulmonary embolus. You know that aspirin is used in the treatment of other acute thromboembolic conditions eg CVA or MI, and in the prophylaxis

2005 BestBETS

404. Narrative review: aspirin resistance and its clinical implications. (PubMed)

Narrative review: aspirin resistance and its clinical implications. Aspirin is currently the most cost-effective drug for the secondary prevention of cardiovascular disease, but treatment failures are relatively common. Several factors have been linked to these recurrent vascular events in patients prescribed aspirin, including smoking, drug interactions, nonadherence, comorbid conditions, and aspirin resistance. The term aspirin resistance has been used to describe not only an absence (...) of the expected pharmacologic effects of aspirin on platelets but also poor clinical outcomes, such as recurrent vascular events, in patients treated with aspirin. Aspirin resistance is perhaps more precisely understood as the phenomenon of measurable, persisting platelet activation that occurs in patients prescribed a therapeutic dose of aspirin and may underlie an unknown proportion of aspirin treatment failures. Key challenges for future research are to standardize a definition of aspirin resistance

2005 Annals of Internal Medicine

405. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. (PubMed)

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Although clopidogrel plus aspirin is more effective than aspirin alone in preventing subsequent vascular events in patients with unstable angina, the cost-effectiveness of this combination has yet to be examined in this high-risk population.To determine the cost-effectiveness of clopidogrel plus aspirin compared with aspirin alone.Cost-utility (...) analysis.Published literature.Patients with unstable angina and electrocardiographic changes or non-Q-wave myocardial infarction. time horizon: Lifetime.Societal.Combination therapy with clopidogrel, 75 mg/d, plus aspirin, 325 mg/d, for 1 year, followed by aspirin monotherapy, was compared with lifelong aspirin therapy, 325 mg/d.Lifetime costs, life expectancy in quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio.Patients treated with aspirin alone lived 9.51 QALYs after

2005 Annals of Internal Medicine

406. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden Lindgren P, Stenestrand U, Malmberg K, Jonsson B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined percutaneous coronary intervention (PCI) with clopidogrel plus aspirin versus aspirin alone in patients with unstable coronary artery disease (CAD). Type of intervention Treatment. Economic study type Cost-effectiveness

2005 NHS Economic Evaluation Database.

407. Analysis of aspirin-associated risks in healthy individuals

Analysis of aspirin-associated risks in healthy individuals Analysis of aspirin-associated risks in healthy individuals Analysis of aspirin-associated risks in healthy individuals Hur C, Simon L S, Gazelle G S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The study examined the use aspirin 325 mg daily in healthy individuals. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of healthy individuals of 50 years of age. Setting The setting was primary care. The economic study was carried out in the USA. Dates to which data relate The effectiveness data and some resource use data were derived from studies published

2005 NHS Economic Evaluation Database.

408. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone Schleinitz M D, Heidenreich P A Record (...) (75 mg/day) plus aspirin (325 mg/day). Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients with unstable angina or non-Q wave MI. The patients included in the analysis were suffering from an ACS characterised by electrocardiographic changes or elevated serum cardiac markers in association with chest pain. Patients who had prolonged ST-segment elevation, or who had undergone

2005 NHS Economic Evaluation Database.

409. A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin

A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin Article Text Clinical prediction guide A prediction rule identified

Full Text available with Trip Pro

2005 Evidence-Based Medicine (Requires free registration)

410. Prevention of preeclampsia with low-dose aspirin: a systematic review and meta-analysis of the main randomized controlled trials

Prevention of preeclampsia with low-dose aspirin: a systematic review and meta-analysis of the main randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

411. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. (PubMed)

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. Concurrent therapy with a proton-pump inhibitor is a standard treatment for patients receiving aspirin who are at risk for ulcer. Current U.S. guidelines also recommend clopidrogel for patients who have major gastrointestinal intolerance of aspirin. We compared clopidogrel with aspirin plus esomeprazole for the prevention of recurrent bleeding from ulcers in high-risk patients.We studied patients who took aspirin (...) to prevent vascular diseases and who presented with ulcer bleeding. After the ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either 75 mg of clopidogrel daily plus esomeprazole placebo twice daily or 80 mg of aspirin daily plus 20 mg of esomeprazole twice daily for 12 months. The end point was recurrent ulcer bleeding.We enrolled 320 patients (161 patients assigned to receive clopidogrel and 159 to receive aspirin plus esomeprazole). Recurrent ulcer

Full Text available with Trip Pro

2005 NEJM Controlled trial quality: uncertain

412. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. (PubMed)

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke. There are few similar data in women.We randomly assigned 39,876 initially healthy women 45 years of age or older to receive 100 mg of aspirin on alternate days or placebo and then monitored them for 10 years for a first major (...) cardiovascular event (i.e., nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes).During follow-up, 477 major cardiovascular events were confirmed in the aspirin group, as compared with 522 in the placebo group, for a nonsignificant reduction in risk with aspirin of 9 percent (relative risk, 0.91; 95 percent confidence interval, 0.80 to 1.03; P=0.13). With regard to individual end points, there was a 17 percent reduction in the risk of stroke in the aspirin group, as compared

2005 NEJM Controlled trial quality: predicted high

413. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. (PubMed)

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate reperfusion or reocclusion of the infarct-related artery, leading to an increased risk of complications and death.We enrolled 3491 patients, 18 to 75 years of age, who presented within 12 hours after the onset of an ST-elevation myocardial infarction (...) and randomly assigned them to receive clopidogrel (300-mg loading dose, followed by 75 mg once daily) or placebo. Patients received a fibrinolytic agent, aspirin, and when appropriate, heparin (dispensed according to body weight) and were scheduled to undergo angiography 48 to 192 hours after the start of study medication. The primary efficacy end point was a composite of an occluded infarct-related artery (defined by a Thrombolysis in Myocardial Infarction flow grade of 0 or 1) on angiography or death

Full Text available with Trip Pro

2005 NEJM Controlled trial quality: predicted high

414. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. (PubMed)

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. Basic research and observational evidence as well as results from trials of colon polyp recurrence suggest a role for aspirin in the chemoprevention of cancer.To examine the effect of aspirin on the risk of cancer among healthy women.In the Women's Health Study, a randomized 2 x 2 factorial trial of aspirin and vitamin E conducted between September 1992 and March 2004, 39 876 US women (...) aged at least 45 years and initially without previous history of cancer, cardiovascular disease, or other major chronic illness were randomly assigned to receive either aspirin or aspirin placebo and followed up for an average of 10.1 years.A dose of 100 mg of aspirin (n=19 934) or aspirin placebo (n=19 942) administered every other day.Confirmed newly diagnosed invasive cancer at any site, except for nonmelanoma skin cancer. Incidence of breast, colorectal, and lung cancer were secondary end

Full Text available with Trip Pro

2005 JAMA Controlled trial quality: predicted high

415. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. (PubMed)

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary syndromes without ST-segment elevation, but its effects in patients with ST-elevation MI were unclear.45,852 patients admitted to 1250 hospitals within 24 h (...) of suspected acute MI onset were randomly allocated clopidogrel 75 mg daily (n=22,961) or matching placebo (n=22,891) in addition to aspirin 162 mg daily. 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to continue until discharge or up to 4 weeks in hospital (mean 15 days in survivors) and 93% of patients completed it. The two prespecified co-primary outcomes were: (1) the composite of death, reinfarction, or stroke; and (2) death from any cause during

2005 Lancet Controlled trial quality: predicted high

416. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. (PubMed)

Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. Atherosclerotic intracranial arterial stenosis is an important cause of stroke. Warfarin is commonly used in preference to aspirin for this disorder, but these therapies have not been compared in a randomized trial.We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target (...) international normalized ratio, 2.0 to 3.0) or aspirin (1300 mg per day) in a double-blind, multicenter clinical trial. The primary end point was ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke.After 569 patients had undergone randomization, enrollment was stopped because of concerns about the safety of the patients who had been assigned to receive warfarin. During a mean follow-up period of 1.8 years, adverse events in the two groups included death (4.3 percent

Full Text available with Trip Pro

2005 NEJM Controlled trial quality: predicted high

417. Aspirin sensitivity: implications for patients with coronary artery disease. (PubMed)

Aspirin sensitivity: implications for patients with coronary artery disease. Although acetylsalicylic acid (aspirin) is commonly used for patients with chronic cardiovascular disease, a minority of patients have a sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs.To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary artery disease (CAD).Published (...) articles were identified through a search of MEDLINE and the Cochrane databases using the dates 1966 to June 2004 and the search terms aspirin allergy, coronary artery disease, aspirin desensitization, and aspirin sensitivity. References of retrieved articles were also reviewed for pertinent studies. Articles were included in this review if they were controlled studies, published in the English language, and appeared in a peer-reviewed journal.The prevalence of aspirin-exacerbated respiratory tract

Full Text available with Trip Pro

2004 JAMA

418. Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer

Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Article Text Therapeutics Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Free James E Shaw

Full Text available with Trip Pro

2004 Evidence-Based Medicine (Requires free registration)

419. Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk

Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Article Text Therapeutics Chemoprophylaxis with aspirin (81 mg daily

Full Text available with Trip Pro

2004 Evidence-Based Medicine (Requires free registration)

420. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page

2004 NIHR HTA programme